Intuitive Surgical continues to compound through rising procedures, a larger installed base, and an increasingly recurring revenue mix. The main debate is whether that quality justifies the stock’s premium valuation.
Intuitive Surgical(ISRG) remains one of the cleanest compounders in large-cap medtech. The core case rests on three hard facts. First, revenue reached $10.06B in 2025, up from $8.35B in 2024, and Q1 2026 revenue rose another 23% YoY to $2.77B. Second, the business model is increasingly recurring, with 84% of 2025 revenue and 86% of Q1 2026 revenue tied to instruments, accessories, service, and lease revenue rather than one-time system sales. Third, the installed base and procedure engine continue to expand at scale: da Vinci procedures grew 16% in Q1 2026 to 847,000, Ion procedures grew 39% to 43,000, and the global da Vinci installed base reached 11,395 systems as of March 31, 2026.
That combination gives ISRG a rare mix of growth and durability. Instruments and Accessories generated $6.02B in 2025, or 59.8% of total revenue, while Services added $1.57B, or 15.6%. Those two streams alone represented more than three-quarters of annual revenue. In plain English, once a hospital adopts the platform and surgeons build workflow around it, the revenue flywheel shifts from selling a robot to supplying an ecosystem.
The main pushback is valuation. ISRG trades at 52.66x trailing earnings, 40.98x forward earnings, and 13.83x EV/revenue, with a PEG ratio of 2.23. Those are premium multiples even for a category leader. The stock therefore suits a balanced, moderate-risk investor only when the entry price leaves room for execution noise in China, tariff pressure, or a slower procedure-growth year. The business is high quality. The stock is less forgiving.
Intuitive Surgical(ISRG), founded in 1995 and headquartered in Sunnyvale, California, develops robotic-assisted platforms used in minimally invasive care. The company operates in Health Care Equipment and had 17,021 employees. Its flagship franchise is the da Vinci surgical system, while Ion extends the company into robotic bronchoscopy for lung biopsy and diagnosis.
Leadership changed at the top in 2026, with David Rosa serving as CEO and Gary Guthart moving to Executive Chair. On the Q1 2026 call, Rosa described the quarter as "a solid start to the year" driven by 17% total procedure growth and broad-based adoption across da Vinci and Ion. That is a useful summary of where the company stands: still the incumbent, but still growing fast enough to act like a challenger.
ISRG reports revenue across three operating buckets: Instruments and Accessories, Services, and Systems. In 2025, Instruments and Accessories produced $6.02B, up from $5.08B in 2024. Services generated $1.57B, up from $1.31B. Systems revenue reached $2.47B, up from $1.97B. Each line grew, but the mix tells the real story: consumables and service remain the economic center of gravity.
Instruments and Accessories represented 59.8% of 2025 revenue. This is the razor-blades engine. In Q1 2026, I&A revenue rose 23% to $1.7B, and da Vinci I&A revenue per procedure increased to about $1,880 from $1,780 a year earlier. Management tied that increase to customer ordering patterns, a higher mix of SP and da Vinci 5 procedures, and FX, partly offset by lower bariatric mix.
Services represented 15.6% of 2025 revenue and are tied to the expanding installed base. Q1 2026 service revenue rose 19% to $434M, reflecting a 12% increase in the da Vinci installed base and a 22% increase in the Ion installed base. Service revenue per da Vinci system increased 6% YoY, helped by a higher mix of da Vinci 5 systems.
Systems represented 24.6% of 2025 revenue. This line is more cyclical because it depends on hospital capital budgets, leasing preferences, trade-ins, and regional tenders. Even so, Q1 2026 systems revenue increased 24% to $651M. The company placed 431 da Vinci systems in the quarter, up from 367 a year earlier, including 232 da Vinci 5 systems, 34 SP systems, and 34 XiR systems. It also placed 52 Ion systems versus 49 a year earlier.
The segment takeaway is straightforward. Systems sales open the door, but recurring revenue pays the rent. When recurring revenue is 86% of quarterly sales, the business starts to look less like a device vendor and more like a procedure platform.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The flagship product remains da Vinci, and the current growth driver inside that franchise is da Vinci 5. In Q1 2026, Intuitive placed 232 da Vinci 5 systems, and management said the installed base was almost 1,500 systems used by almost 13,000 surgeons since launch. The investor presentation also showed da Vinci 5 utilization running 11% higher than Xi. Higher utilization matters more than launch headlines because it signals that the platform is not just being bought, it is being worked.
Procedure growth supports that view. da Vinci procedures grew 16% in Q1 2026 to 847,000. In the U.S., da Vinci procedures grew 14%, led by general surgery, while outside the U.S. they grew 19%. Management highlighted 31% growth in U.S. cholecystectomy and appendectomy procedures and 19% growth in non-hysterectomy benign gynecology procedures. Those figures show the platform broadening beyond its older urology-heavy base.
Single Port, or SP, is still smaller but moving quickly. SP procedures grew 68% YoY in Q1 2026, and the 2025 investor presentation showed 55,000+ SP procedures, 370+ installed systems, and 39% installed-base growth. The SP stapler moved into broad U.S. launch during Q1, and management said it was used in almost 40% of cases where a stapler would be expected. That is the kind of attachment-rate data that turns a platform from promising to monetizable.
Ion is the second major product pillar. Q1 2026 Ion procedures increased 39% to 43,000, and the installed base reached 1,041 systems as of March 31, 2026. The 2025 presentation showed 140,000+ Ion procedures and 990+ installed systems in 2025, with utilization up 9% YoY. Ion is still much smaller than da Vinci, but it gives ISRG a second clinical growth lane in lung diagnostics.
That line from David Rosa is not just polished corporate language. It is backed by clinical data cited on the call. A Mayo Clinic study covering 2,115 peripheral pulmonary lesions from 1,904 patients reported a 79% diagnostic yield, 85% sensitivity for malignancy, a 1.4% pneumothorax intervention rate, and a 0.3% severe bleeding rate. The rate of early-stage primary lung cancer diagnosis in that study increased from 46% in 2019 to 69% in 2024. For a platform business, clinical evidence is a sales tool with a lab coat on.
ISRG’s moat starts with scale. The company had 11,395 da Vinci systems installed worldwide as of March 31, 2026, including 6,477 in the U.S., 2,257 in Europe, 2,049 in Asia, and 612 in the rest of the world. It also had 1,041 Ion systems installed. That base feeds recurring revenue, surgeon familiarity, hospital workflow integration, and data collection. Competitors can build hardware. Rebuilding a global installed ecosystem is a different job entirely.
Training is another moat layer. Intuitive said it has more than 101,000 da Vinci-trained surgeons globally. That matters because robotic surgery adoption is not just a capital purchase. It is training, credentialing, workflow redesign, and clinical support. Once a hospital and surgeon team commit, switching costs are real even if they do not show up neatly on a balance sheet.
The next moat layer is data and digital capability. Rosa said da Vinci 5 captures real-world surgical data at greater scale and fidelity, including video, kinematic data, and force data. He framed this as the foundation for AI-enabled anatomy identification, deeper decision support, augmented dexterity, and eventually aspects of automation. The important point is not futuristic language by itself. It is that Intuitive already has the installed base and procedure volume to generate proprietary data at scale.
Force Feedback is a concrete example. In March, the company received FDA 510(k) clearance for additional uses of its Force Feedback instruments. Five of six instruments are now cleared for 15 uses, and the Mega SutureCut Needle Driver is cleared for 10 uses. Management said this, combined with multiyear supply-chain and manufacturing investments, supports broader availability in Q2 2026 and increasing availability through the year.
Innovation is also showing up in economics. CFO Jamie Samath said Q1 2026 revenue growth ahead of total procedure growth reflected the differentiated value of da Vinci 5, with accretive pricing, higher integration, and incremental trade-ins. When a next-gen platform lifts both utilization and ASP, that is a strong sign the product cycle is doing real work.
Operations are a quiet strength here. Q1 2026 non-GAAP gross margin reached 67.8%, up from 66.4% a year earlier, driven by product cost reductions and fixed overhead leverage, partly offset by tariffs. Management also said the da Vinci 5 system achieved contribution margins comparable with Xi during the quarter, while Ion contribution margins were close to the corporate average. That is a meaningful milestone because newer platforms often carry a launch tax before scale catches up.
Manufacturing scale remains a strategic priority. Management listed building industrial scale, enhancing product quality, and achieving manufacturing optimization as 2026 priorities. The company added 425 employees during Q1, including 230 tied to the acquisition of its distribution business in Italy, Spain, and Portugal. That move should improve direct commercial control in Southern Europe over time.
There are still cost pressures to watch. Management said higher oil and memory prices were not a major Q1 issue but are expected to have a greater unfavorable impact through the rest of 2026. Tariffs are also embedded in guidance, with the updated 2026 gross margin outlook of 67.5% to 68.5% including a 1.0% revenue impact from tariffs.
Cybersecurity also moved from background risk to named operating issue. Samath disclosed a cyber incident in Q1 that involved unauthorized access to some customer business and contact information and certain employee and corporate data. He also said the incident did not disrupt business or manufacturing operations, did not affect products, and did not have a significant impact on Q1 financial results. That is the right outcome, but in connected medtech, cybersecurity is now part of product credibility, not just IT housekeeping.
The market backdrop remains attractive. Grand View Research estimates the global surgical robots market at $7.6B in 2026, rising to $18.5B by 2033 at a 13.5% CAGR. A related hospital-assisted surgical robot procedures market is estimated at $12.9B in 2026 and $39.4B by 2033. Those figures support the view that robotic surgery is still early in penetration, especially outside legacy specialties.
ISRG’s own numbers line up with that runway. da Vinci procedures exceeded 3.0M in 2025, up 17% YoY in the investor presentation, and company disclosures elsewhere put 2025 da Vinci procedures at 3.153M. For 2026, management raised worldwide da Vinci procedure growth guidance to 13.5% to 15.5%. That is slower than 2025 growth, but still strong for a company already operating at this scale.
Geography is part of the opportunity. Outside-U.S. procedures now represent 38% of total da Vinci volume, up from 25% a decade ago, according to management. The company is seeing strong results in Europe, India, Canada, the U.K., Korea, Taiwan, Italy, Germany, and distributor markets. That broadens the growth base and reduces dependence on any single reimbursement system.
The market is also shifting toward software, data, and workflow integration. FDA guidance on AI/ML software and cybersecurity in medical devices raises the compliance bar, but it also favors incumbents with scale, data, and regulatory muscle. Intuitive is trying to turn that from a cost center into a moat.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
ISRG’s customers are hospitals, health systems, and surgeons, but the buying decision is more layered than a standard equipment sale. Capital committees care about utilization, throughput, and total cost. Surgeons care about workflow, training, and outcomes. Administrators care about reimbursement and service reliability. Intuitive’s model addresses each layer through systems, consumables, service, training, and digital support.
Leasing has become a more important tool for customer acquisition. In Q1 2026, 56% of da Vinci placements were under operating lease arrangements, up from 47% in the prior quarter and 54% a year earlier. Usage-based arrangements lower upfront capex for hospitals and can widen the addressable customer base, especially when budgets are tight.
The company is also seeing evidence of deeper program adoption, not just initial installs. U.S. da Vinci utilization increased 4% in Q1 2026, and da Vinci 5 utilization was about 11% higher than Xi. SP average system utilization in the U.S. grew 22% YoY. Those are signs that customers are expanding use cases after adoption rather than letting systems sit in the corner like expensive furniture.
Intuitive remains the category leader in soft-tissue robotic surgery, but the field is getting more crowded. Medtronic received FDA clearance for Hugo RAS for urologic procedures in December 2025 and reported its first U.S. commercial case on February 17, 2026. Medtronic also submitted 510(k) filings on June 3, 2026 to expand Hugo into general and gynecologic specialties in the U.S. Johnson & Johnson submitted OTTAVA to the FDA in January 2026, though that platform remains earlier in commercialization.
Those developments matter because the battleground is moving toward multi-specialty soft-tissue platforms, which is Intuitive’s home turf. Still, the gap remains wide. ISRG had 11,395 da Vinci systems installed by March 31, 2026, more than 3M annual da Vinci procedures, and more than 101,000 da Vinci-trained surgeons. Competitors are entering a market where the incumbent already owns the installed base, the training pipeline, and the recurring revenue stream.
Competition is more acute in China. Management cited low tender activity, domestic competition, and policy-driven pricing pressure. That is one of the few places where the moat looks less like a castle and more like a border checkpoint.
Ion also faces adjacent competition from other bronchoscopy and biopsy solutions, but its clinical data and installed-base growth give it a credible position. The larger point is that ISRG is no longer a one-product story. That diversification helps, even if da Vinci still carries the franchise.
Macro risk for ISRG is less about consumer demand and more about hospital budgets, reimbursement policy, tariffs, and currency. In 2025, about 24% of revenue was denominated in foreign currencies. The 10-K said a 10% strengthening of the U.S. dollar would have reduced 2025 revenue by about $140M before considering hedges. That makes FX a real earnings variable, not a footnote.
Tariffs are another direct headwind. Management built a 1.0% revenue impact from tariffs into 2026 non-GAAP gross margin guidance. That is manageable, but it matters because ISRG’s premium multiple assumes operational precision. Small margin drags can have an outsized effect when investors are paying over 40x forward earnings.
China remains the biggest geopolitical and policy risk. Management said the environment reflects relatively low tender activity, domestic competition, and policy-driven pricing pressure. Jamie Samath added that discussions with provinces on charge code and reimbursement policies are ongoing, with no expected clarity until 2027. Japan is more mixed: procedure growth improved sequentially, and the Ministry of Health introduced incremental reimbursement for hospitals exceeding 200 qualifying robotic cases per year, plus reimbursement for seven additional procedures starting in June 2026. Even so, management remained cautious because of the financial position of public hospitals.
The macro picture, then, is not broken. It is just less frictionless than the headline growth suggests. ISRG can handle that because it has scale, cash, and recurring revenue. But the stock multiple leaves little room for geopolitical surprises.
With an A+ balance sheet grade, Intuitive Surgical enters 2026 with the kind of financial strength that can absorb execution noise while still funding growth.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Revenue rose from $8.35B in 2024 to $10.06B in 2025, and Q1 2026 sales climbed another 23% to $2.77B, underscoring powerful operating momentum.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q1 2026 procedure growth of 17% overall, including 16% da Vinci growth and 39% Ion growth, gives the outlook a strong near-term tailwind.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →At 52.66x trailing earnings, 40.98x forward earnings, and 13.83x EV/revenue, the stock still commands a premium that leaves less room for disappointment.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s fair value sits at $540, with upside supported by recurring revenue strength but capped by a valuation that already prices in a lot of success.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Intuitive Surgical(ISRG) is still the standard-setter in robotic-assisted surgery. The company grew 2025 revenue to $10.06B, lifted Q1 2026 revenue 23% YoY to $2.77B, generated high margins, and kept expanding both da Vinci and Ion. The installed base, recurring revenue mix, and net-cash balance sheet make this one of the sturdier growth stories in medtech.
The debate is not whether the business is good. It is whether the stock already knows it. With a fair value estimate of $540, the answer is that ISRG still has room to work higher from the cited current-price area, but the margin for error is thinner than it looks at first glance. For a moderate-risk investor, that supports a Buy rating, with discipline on entry price and no illusions about valuation.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Intuitive Surgical just got hit like the growth story broke, yet the quarter said the opposite. Revenue rose 19%, procedures stayed double-digit, and da Vinci 5 placements kept climbing, which makes this look more like an expectations reset than a business problem.
Intuitive Surgical, Inc. (ISRG) falls sharply after its Q2 2026 earnings report, even with an EPS beat. Investors focused on slower U.S. procedure growth and an unchanged outlook, triggering analyst target cuts and a valuation reset.
Intuitive Surgical, Inc. (ISRG) falls sharply after hours after its latest earnings release, even as procedure growth remains strong. The selloff reflects a high valuation, cautious analyst target cuts, and broader medtech weakness, leaving investors focused on whether the premium can hold.